Alentis Therapeutics AG
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alentis.ch
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- Conditions
- Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 170
- Registration Number
- NCT06747585
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Study of ALE.C04 in Patients With Head and Neck Cancer
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT06054477
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Southern California USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Yale University Yale Cancer Center, New Haven, Connecticut, United States
Rescue of Nephrons With ALE.F02 (RENAL-F02)
- Conditions
- Glomerulonephritis Rapidly Progressive
- Interventions
- Drug: PlaceboDrug: Immunosuppressive Agents
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 80
- Registration Number
- NCT06047171
- Locations
- 🇨🇿
Vseobecna fakultni nemocnice v Praze, Prague, Czechia
🇨🇿Institut klinicke a experimentalni mediciny, Praha 4, Czechia
🇩🇰Aalborg University Hospital, Aalborg, Denmark
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/or with Mild Cirrhosis
- Conditions
- Advanced liver fibrosis and/or mild liver cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 37
- Registration Number
- 2024-516455-40-00
- Locations
- 🇷🇴
Arensia Exploratory Medicine S.R.L., Bucharest, Romania
🇷🇴Spitalul Clinic Judetean De Urgenta Cluj, Cluj-Napoca, Romania
🇸🇰Summit Clinical Research s.r.o., Malacky, Slovakia